Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel A Erlanson

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Cell Reports. Medicine|June 3, 2025
Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacyRuben Rodriguez, Anne Hergarden, Shyam Krishnan, et al.
Journal of Medicinal Chemistry|November 1, 2002
Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug designIngrid C Choong, Willard Lew, Dennis Lee, et al.
Molecular Metabolism|November 30, 2025
Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesityManu V Chakravarthy, Ruben Rodriguez, Anne Hergarden, et al.
Bioorganic & Medicinal Chemistry|May 30, 2019
Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screensBrian T Hopkins, Eris Bame, Noah Bell, et al.
Bioorganic & Medicinal Chemistry Letters|April 5, 2011
Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discoveryDaniel A Erlanson, Joseph W Arndt, Mark T Cancilla, et al.
Bioorganic & Medicinal Chemistry|July 27, 2021
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitorsBrian T Hopkins, Eris Bame, Noah Bell, et al.
ACS Medicinal Chemistry Letters|September 19, 2019
Discovery of <i>N</i>-(1-Acryloylazetidin-3-yl)-2-(1<i>H</i>-indol-1-yl)acetamides as Covalent Inhibitors of KRAS<sup>G12C</sup>Youngsook Shin, Joon Won Jeong, Ryan P Wurz, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Cell Reports. Medicine|June 3, 2025
Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacyRuben Rodriguez, Anne Hergarden, Shyam Krishnan, et al.
Journal of Medicinal Chemistry|November 1, 2002
Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug designIngrid C Choong, Willard Lew, Dennis Lee, et al.
Molecular Metabolism|November 30, 2025
Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesityManu V Chakravarthy, Ruben Rodriguez, Anne Hergarden, et al.
Bioorganic & Medicinal Chemistry|May 30, 2019
Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screensBrian T Hopkins, Eris Bame, Noah Bell, et al.
Bioorganic & Medicinal Chemistry Letters|April 5, 2011
Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discoveryDaniel A Erlanson, Joseph W Arndt, Mark T Cancilla, et al.
Bioorganic & Medicinal Chemistry|July 27, 2021
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitorsBrian T Hopkins, Eris Bame, Noah Bell, et al.
ACS Medicinal Chemistry Letters|September 19, 2019
Discovery of <i>N</i>-(1-Acryloylazetidin-3-yl)-2-(1<i>H</i>-indol-1-yl)acetamides as Covalent Inhibitors of KRAS<sup>G12C</sup>Youngsook Shin, Joon Won Jeong, Ryan P Wurz, et al.
Pageof 5